It’s been a wierd couple of months at African genomics startup 54gene. In August, it sacked 95 staff, principally contract workers (in labs and gross sales departments) employed to work in 54gene’s COVID enterprise line launched in 2020. In September, co-founder and VP of Engineering Ogochukwu Francis Osifo left the corporate. And this week, founder and now ex-CEO Dr. Abasi Ene-Obong stepped down from his govt position to be changed by Basic Counsel Teresia L. Bost.
This information coincided with extra job cuts. The corporate confirmed to TechCrunch that this second spherical of layoffs, which occurred on Tuesday, affected over 100 workers: 55% of the whole workforce remaining after the primary spherical of layoffs. The biotech didn’t specify what roles and departments bought trimmed.
The Washington- and Lagos-based genomics startup has been thought-about the showpiece of Africa’s fledging biotech house because it bought into Y Combinator in 2019. However whereas 54gene launched to deal with the hole within the world genomics market, the place Africans make up lower than 3% of genetic materials utilized in pharmaceutical analysis, its progress in 2020 overlapped elsewhere, with the COVID-19 pandemic, and it employed aggressively to satisfy the calls for of being one among Nigeria’s largest suppliers of COVID testing.
Its preparedness to satisfy this chance with its medical diagnostic arm was additionally a catalyst to rising its income and elevating two big progress rounds in fast succession: a $15 million Collection A that 12 months and a $25 million Collection B in 2021 from traders resembling New York-based Adjuvant Capital, Pan-African agency Cathay AfricInvest Innovation Fund (CAIF), KdT Ventures and Endeavor Catalyst.
But, 2022 will likely be a 12 months to neglect for the biotech startup. Not solely has its revenues dwindled and laid off virtually 200 staff, however the firm’s worth has additionally been considerably trimmed in a interval when startups’ valuations are taking a beating. Based on folks with data of the matter, 54gene’s valuation has dropped by two-thirds, from the $170 million secured when it raised its Collection B to about $50 million in a bridge spherical involving lead traders from the corporate’s board.
Sources additionally stated the down spherical closed at a 3x to 4x liquidation desire, which means that traders — usually the lead investor — could be paid again triple or quadruple their cash earlier than different stakeholders, together with different traders, founders and staff within the case of an exit. These phrases, which shift energy again to traders, had been uncommon through the enterprise capital increase between mid-2020 and final 12 months however are actually commonplace on this fundraising setting.
54gene didn’t verify or deny the premise of this deal. Nonetheless, it acknowledged in an electronic mail response: “The prevailing traders injected recent capital into the corporate at phrases that replicate present market situations. We hope this spherical not solely helps the corporate by means of this difficult interval but additionally positions it for achievement sooner or later — whether or not it’s to boost further capital, appeal to strategic companions, or one other future path.”
Usually, liquidation preferences sign that traders wish to defend themselves if a growth-stage portfolio firm exits at a worth decrease than initially anticipated. In some circumstances, the traders imagine that the startup may wrestle to provide a stable exit because of underlying challenges affecting its enterprise.
When the corporate’s first layoff information broke, allegations of economic impropriety had been leveled in opposition to the then-CEO and his executives from a bunch of staff. And although they continue to be unfounded, these accusations have come to gentle once more following Ene-Obong’s resignation. Affected staff — who declare they haven’t obtained their severance packages and spoke to TechCrunch on the situation of anonymity — unsubstantially blame 54gene’s present troubles on irresponsible hiring, questionable growth drives and misappropriation of funds. The YC-backed biotech didn’t reply to TechCrunch’s request for feedback about its former executives’ alleged mismanagement of funds and staff’ unpaid severance packages.
54gene’s tight-lippedness on the matter and Bost’s appointment from her authorized position to interim CEO arbitrarily raises questions and leaves room for interpretation tilting towards these accusations, particularly as each co-founders resigned just a few weeks aside. Nevertheless, in an electronic mail to TechCrunch, the corporate subtly counterargues that Osifo’s resignation had been in course of for a while and was unrelated to this month’s actions, whereas Bost, employed final September, was what 54gene wanted — with assist from COO Delali Attipoe — for its subsequent section.
“Teresia is a well-rounded govt with a depth of expertise within the world pharmaceutical and biotech trade, main world groups and overseeing company governance,” the corporate stated. “These expertise, coupled along with her breadth of expertise driving enterprise operations and translating complicated regulatory necessities, will likely be invaluable on the helm of 54gene on this subsequent section of the corporate. Delali and Teresia will make a terrific staff that collectively will strengthen 54gene’s place as a genomics chief within the trade.”
In the meantime, 54gene acknowledged that its ex-chief govt “will proceed to assist the corporate in its go-forward plans resembling strategic partnerships and fundraising” with out explaining why he stepped down.
Nevertheless, in keeping with a number of folks with data of happenings on the firm, the phrases of 54gene’s new deal contributed to Ene-Obong’s resignation. They are saying Ene-Obong — retaining his place on 54gene’s board whereas transferring to a brand new senior advisor position — could have resigned as CEO in protest of 54gene’s new valuation and the liquidation desire supplied by traders within the bridge spherical. There’s some hypothesis that a few of the traders additionally tried to reprise the corporate’s earlier prized spherical to get extra shares whereas diluting that of the founders and different traders. 54gene declined to touch upon the matter.
The truth that 54gene needed to organize a bridge spherical in-house regardless of securing over $45 million during the last three years is a reminder that biotech tasks are extremely capital-intensive — as an example, it prices about $700 to sequence a human genome (one among 54gene’s predominant procedures). Usually, biotechs deploy traders’ funds into analysis whereas fascinated by income later and the case isn’t totally different with 54gene. Nonetheless, the style during which the genome startup is aggressively slicing prices by shedding workers in two batches– and shutting down its medical diagnostic arm — is considerably troubling regardless of the plain results of the pandemic. This present disaster, coupled with the arduous activity forward of the corporate, has additionally led many tech observers to surprise if its current and previous executives can hold the moonshot challenge afloat lengthy sufficient to generate substantial income, not to mention construct a stable enterprise.
